1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369～372.
2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ～ 14.
3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129～153.
4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393～ 1399.
5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204～211.
6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792～1823.
7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413～423.
8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27～31.
9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873～888.
10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395～1409.
4CHEN X L,JIN Y Y,TANG G. Materia Medica New Edition(新编药物学) [ M]. 15th ed,Beijing:People's Health Press,2003:617.
5Hanefeld M, Marx N, Pfutzner A, et al. Antiinflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity Creactive protein:the PIOSTAT study [ J ]. J Am Coll Cardio1,2007,49 ( 3 ) :290-297.
6Hanefeld M, Marx N, Pfutzner A, et al. Antiinflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity Creactive protein:the PIOSTAT study [ J ]. J Am Coll Cardio1,2007,49 ( 3 ) :290-297.
7Yang WY,Lu JM,Weng JP,et al.Prevalence of Diabetes among men and women in China.N Engl J Med,2010,362:1090-1101.
8Chen YW, Chen YC, Wu CJ, et al. Massive Bilateral Pleural Effusion Associated with Use of Pioglitazone [J]. Clinical Therapeutics, 2008, 30(8):1485-1489.
9Tan M, Johns D, Guillermo Gonzalez,et al. Effects of Pioglitazone and Glimepiride on Glycemic Control and Insulin Sensitivity in Mexican Patients with Type 2 Diabetes Mellitus:A Multicenter, Randomized,Double-Blind, Parallel-Group Trial[J].Clinical therapeutics,2004,26(5):680-93.
10Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a Meta-analysis[J].Diabetes Res Clin Prac,2007,76( 2):279-289.
